Page results
-
Two clinicians with close links to UCLH and UCL have been appointed to be National Clinical Directors (NCD) by NHS England (NHSE) for 2024.
-
Dr Tim Yates has a particular interest in the management of refractory headache disorders, particularly chronic migraine, the trigeminal autonomic cephalalgias, and facial pain syndromes.
-
The Com-Cov trial in which UCLH is a site looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines.
-
UCLH consultant Dr Arjuna Nagendran featured in the Royal Institution’s prestigious series on Boxing Day; this year presented by Professor Mike Woolridge on artificial intelligence (AI).
-
The designs of a new breathing aid developed by engineers at UCL and Formula One working with clinicians at UCLH have been made freely available to support the global response to Covid-19.
-
Minimally invasive therapies for prostate cancer which remove the cancer while leaving the rest of the prostate intact are beneficial for patients and cost effective according to new research.
-
Professor Beate Diehl is a consultant neurologist, clinical neurophysiologist and clinical senior lecturer.
-
Achilles Therapeutics, a company built on research at UCLH, UCL Cancer Institute and the Francis Crick Institute has successfully raised $175.5 million through its initial public offering in the United States.
-
Prime Minister Boris Johnson came to the UCLH vaccination centre based at The Francis Crick Institute to receive his second COVID-19 vaccination.
-
Winning the award - Sarcoma Healthcare Professionals Innovation and Excellence – CNS London Sarcoma Service, The National Sarcoma Educational Programme. Jo and Anne had the vision of sharing a regular in-house education session to bring sarcoma nurses and doctors together. These monthly sessions have seen a broad range of speakers and experts in the sarcoma field from other sarcoma units, charities and researchers sharing their knowledge.
File results
-
FOI/2024/0318 - Patients absconded from medium/ high-security psychiatric facilities
-
FOI/2024/0320 - Treatment for rare diseases; fabry, gaucher and pompe diseases
-
FOI/2024/0326 - Treatment of Haemophilia B and Von Willebrand disease
-
FOI/2024/0327 - Treatment of non-UK nationals
-
FOI/2024/0329 - Metastatic renal cell carcinoma patients/ classification
-
FOI/2024/0464 - Theatre sessions/ productivity
-
FOI/2024/0467 - Drug Patient Level Contract Monitoring (DrPLCM) and SACT Cancer reports
-
FOI/2024/0333 - Elective treatment wait over 65 weeks
-
FOI/2024/0337 - IVF clinical unit/ embryology laboratory
-
FOI/2024/0338 - Ophthalmology outpatient activity 2022, 2023 and 2024